Bluejay Diagnostics (BJDX) Director Fred Zeidman Receives Option Award

What Happened

• Fred S. Zeidman, a director of Bluejay Diagnostics (BJDX), received a grant of 100,000 stock options on 2026-08-17. The grant was reported as an award/derivative (code A) with an acquisition price of $0.00, so there was no cash exchanged at grant.
• The options are described as out-of-the-money and will vest and become exercisable at a strike price of $2.075 per share on the first anniversary of the grant date — but only if and after the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device. Because of that contingency, there is no immediate intrinsic value or ability to exercise.

Key Details

• Transaction date: 2026-08-17; filing date: 2026-08-18 (timely filing).
• Grant: 100,000 options; reported acquisition price $0.00 (award/derivative).
• Strike price: $2.075 per share; vesting/exercisability: on first anniversary of grant and contingent on FDA clearance/approval of the Symphony IL-6 device.
• The filing characterizes the award as out-of-the-money (no current intrinsic value).
• Shares/options held after the transaction are not specified in the provided filing excerpt.
• Not an open-market purchase or sale — this is a compensation award, not a direct buy or sale.

Context

• This grant is compensation-based and does not require Zeidman to pay now; it creates potential future dilution if and when options vest and are exercised.
• Because exercisability is conditional on FDA clearance, the options carry regulatory contingency risk — they may never become exercisable if approval/clearance is not obtained.
• As with most option grants to insiders, this is primarily a retention/incentive tool and should not be interpreted as an immediate bullish or bearish trade signal on its own.